Back to today’s briefing

Story perspectives

Trodelvy and Keytruda Combo Revolutionizes Triple-Negative Cancer Treatment

4/21/2025

36 8

Summary

Story summary

Gilead Sciences has unveiled promising results from the Phase 3 ASCENT-04 trial, revealing that its cancer drug Trodelvy, when paired with Merck's Keytruda, dramatically slows tumor growth in patients battling metastatic triple-negative breast cancer. This powerful combination not only enhances progression-free survival but also opens doors to new treatment possibilities in a competitive landscape.

1 of 1

Story summary

Gilead Sciences has unveiled promising results from the Phase 3 ASCENT-04 trial, revealing that its cancer drug Trodelvy, when paired with Merck's Keytruda, dramatically slows tumor growth in patients battling metastatic triple-negative breast cancer. This powerful combination not only enhances progression-free survival but also opens doors to new treatment possibilities in a competitive landscape.